The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMercia Asset Regulatory News (MERC)

Share Price Information for Mercia Asset (MERC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 32.70
Bid: 32.00
Ask: 33.40
Change: 0.00 (0.00%)
Spread: 1.40 (4.375%)
Open: 32.70
High: 32.70
Low: 32.70
Prev. Close: 32.70
MERC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Edison Investment Research Limited: Mercia Asset Management (MERC): The UK's top regional investor

3 Mar 2021 07:00

Edison Investment Research Limited Edison Investment Research Limited: Mercia Asset Management (MERC): The UK's top regional investor 03-March-2021 / 07:00 GMT/BST


 

London, UK, 3 March 2021

 

Mercia Asset Management (MERC): The UK's top regional investor

The £30.7m cash exit from Oxgene underlines management's success in building a sustainably profitable specialist asset manager, delivering high levels of contracted revenue and providing a filtered pipeline of opportunities for Mercia's direct investment portfolio. Based on progress to date, we believe Mercia will achieve its three-year strategic plan ahead of time (grow operating profitability, expand assets under management (AUM) to £1bn and 'evergreen' the balance sheet by end FY22). By the end of H121, AUM had risen to £872m (15% from FY22 target), with fee-earning funds under management (FUM) of £722m. Despite progress, Mercia's shares continue to trade at a material 21% discount to net assets (0.79x) or a 30-35% discount when we include the third-party funds business (worth 4.9p at 3% of FUM). This is a substantial discount to its peers.

 

Although profitable and dividend paying, with a mature, evergreen balance sheet, and scaling AUM, Mercia still trades at a 21% discount to its H121 NAV (34.1p per share) and a significant discount to its peers. Together with its fund management arm (5-8p per share), the overall valuation rises to 39-42p per share, implying a discount of closer to 31-36%. Catalysts for a re-rating include further scaling of the business, continuing revenue/earnings growth, commercialisation of the direct investment portfolio and/or successful exits.  

Click here to view the full report or here to sign up to receive research as it is published.

 

All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.

Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Richard Williamson +44 (0)20 3077 5700 tech@edisongroup.com

Rob Murphy +44 (0)20 3077 5700 tech@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on:

LinkedIn https://www.linkedin.com/company/edison-group-/

Twitter  www.twitter.com/Edison_Inv_Res

YouTube www.youtube.com/edisonitv


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

1172526 03-March-2021 

corporate announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
2nd Dec 20207:00 amRNSPerformance fee entitlement
1st Dec 20207:00 amRNSInterim Results
27th Nov 20207:00 amRNSInvestor Presentation
6th Nov 20207:00 amRNSNotice of Results and Investor Presentations
3rd Nov 20207:00 amRNSBoard Appointment
30th Oct 20207:30 amRNSNew direct investment into Sense Biodetection
19th Oct 20207:00 amRNSSuccessful exit of Clear Review
7th Oct 20207:00 amRNSWarwick Acoustics Update
25th Sep 20207:00 amRNSDirector/PDMR Dealings
24th Sep 202010:29 amRNSResult of AGM
24th Sep 20207:00 amRNSAGM Statement
18th Sep 20207:00 amRNSLife Sciences’ Portfolio Update
24th Aug 20207:00 amRNSGrant of Options
31st Jul 20207:03 amRNSPublication of Annual Report
29th Jul 20202:31 pmRNSDirector/PDMR Dealings
14th Jul 20207:00 amRNSPreliminary results
9th Jul 20207:00 amRNSSale of The Native Antigen Company
1st Jul 20207:00 amRNSPortfolio company MIP Diagnostics raises £5.1m
11th Jun 20207:00 amRNSNotice of Results
27th May 202011:08 amRNSMercia accredited by BBB under CBILS
14th May 20207:00 amRNSMedherant partners with Cycle Pharmaceuticals
6th May 20207:00 amRNSInvestment into OXGENE
21st Apr 20207:00 amRNSBritish Business Bank increases Mercia’s mandate
3rd Apr 202012:47 pmRNSNVM VCTs raise £38.2 million
2nd Apr 20207:00 amRNSPortfolio companies collaborate against COVID-19
27th Mar 202011:30 amRNSDirector/PDMR Dealings
25th Mar 20203:08 pmRNSCOVID-19 Business Update
25th Mar 20201:42 pmRNSNotification of Major Holdings
18th Mar 202010:59 amRNSNOTIFICATION OF MAJOR HOLDINGS
11th Mar 20204:18 pmRNSNOTIFICATION OF MAJOR HOLDINGS
4th Feb 20203:20 pmRNSNOTIFICATION OF MAJOR HOLDINGS
4th Feb 20203:20 pmRNSPDMR / Director Dealings
4th Feb 20208:50 amRNSNotification of Major Holdings
4th Feb 20207:00 amRNSHolding in Company
29th Jan 20207:00 amRNSGrant of Options
22nd Jan 202012:49 pmRNSForm 8.3 - RedX Pharma PLC
17th Jan 20204:45 pmRNSNotification of Major Holdings
16th Jan 20207:00 amRNSnDreams makes continuing commercial progress
9th Jan 20202:06 pmRNSNOTIFICATION OF MAJOR HOLDINGS
9th Jan 20202:00 pmRNSNOTIFICATION OF MAJOR HOLDINGS
31st Dec 201910:55 amRNSNotification of Major Holdings
30th Dec 201911:57 amRNSNOTIFICATION OF MAJOR HOLDINGS
30th Dec 201911:36 amRNSNOTIFICATION OF MAJOR HOLDINGS
27th Dec 201912:01 pmRNSNOTIFICATION OF MAJOR HOLDINGS
24th Dec 201912:16 pmRNSNOTIFICATION OF MAJOR HOLDINGS
23rd Dec 20193:36 pmRNSNOTIFICATION OF MAJOR HOLDINGS
23rd Dec 20192:14 pmRNSNOTIFICATION OF MAJOR HOLDINGS
23rd Dec 20192:04 pmRNSCompletion of Acquisition
23rd Dec 201912:44 pmRNSNOTIFICATION OF MAJOR HOLDINGS
23rd Dec 20199:49 amRNSDirector/PDMR Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.